CMV in the HSCT Recipient

Allogenic Stem Cell Transplantation Where Are We?

CMV Infections After HSCT

Concerns for Increased Risk of CMV Infection

Burden of Disease Mortality and Cost

Approaches to CMV Preemptive Therapy

Approaches to CMV Testing

CMV VL Testing Challenges

Considerations When Monitoring CMV VL

Preemptive Strategies DNA CMV Polymerase Inhibitors

Concerns With Prophylaxis

Where Have We Made Progress?

Maribavir: Treatment Phase 2: Initially Promising

Maribavir: Prophylaxis Phase 3: No Difference When Compared With PBO

Brincidofovir for CMV Prevention Phase 2

Brincidofovir for CMV Prevention Phase 3

Letermovir for CMV Prevention Phase 3

Letermovir Safety Results

Impacts on Practice Use of Letermovir

Impacts on Practice Drug-Drug Concerns

Moving Forward

Concluding Remarks

Abbreviations

Abbreviations (cont)